These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31461404)

  • 1. Thyroid Disease (TD), Chronic Obstructive Pulmonary Disease (COPD) and Valvular Heart Disease (VHD) as modifiable risk factors of Atrial Fibrillation.
    Tsagkaris C; Zacharopoulou L
    Rom J Intern Med; 2020 Mar; 58(1):3-4. PubMed ID: 31461404
    [No Abstract]   [Full Text] [Related]  

  • 2. Treat thyroid disease to help protect your heart. Thyroid disease can sometimes cause heart palpitations, but even worse it can increase your risk of atrial fibrillation.
    Heart Advis; 2011 Apr; 14(4):4. PubMed ID: 22973587
    [No Abstract]   [Full Text] [Related]  

  • 3. Influence of atrial fibrillation on microRNA expression profiles in left and right atria from patients with valvular heart disease.
    Cooley N; Cowley MJ; Lin RC; Marasco S; Wong C; Kaye DM; Dart AM; Woodcock EA
    Physiol Genomics; 2012 Feb; 44(3):211-9. PubMed ID: 22147268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of atrial fibrillation in patients with chronic obstructive pulmonary disease.
    Lopez CM; House-Fancher MA
    J Cardiovasc Nurs; 2005; 20(2):133-40. PubMed ID: 15855862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
    Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B;
    Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
    De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation).
    Thomas KL; Jackson LR; Shrader P; Ansell J; Fonarow GC; Gersh B; Kowey PR; Mahaffey KW; Singer DE; Thomas L; Piccini JP; Peterson ED
    J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29273635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calreticulin overexpression correlates with integrin-α5 and transforming growth factor-β1 expression in the atria of patients with rheumatic valvular disease and atrial fibrillation.
    Zhao F; Zhang S; Shao Y; Wu Y; Qin J; Chen Y; Chen L; Gu H; Wang X; Huang C; Zhang W
    Int J Cardiol; 2013 Oct; 168(3):2177-85. PubMed ID: 23465222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Valvular Heart Disease on Mortality, Thromboembolic and Cardiac Events in Japanese Patients With Atrial Fibrillation　- The Fushimi AF Registry.
    Doi K; Ogawa H; Ishigami K; Ikeda S; Aono Y; Hamatani Y; Fujino A; An Y; Ishii M; Iguchi M; Masunaga N; Esato M; Tsuji H; Wada H; Hasegawa K; Abe M; Akao M;
    Circ J; 2020 Apr; 84(5):714-722. PubMed ID: 32213725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of atrial fibrillation with reference to valvular heart disease.
    Mehta D; Ghosh J
    Indian Heart J; 2002; 54(3):312-20. PubMed ID: 12216934
    [No Abstract]   [Full Text] [Related]  

  • 11. Detrimental Impact of Chronic Obstructive Pulmonary Disease in Atrial Fibrillation: New Insights from Umbria Atrial Fibrillation Registry.
    Angeli F; Reboldi G; Trapasso M; Aita A; Ambrosio G; Verdecchia P
    Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31324041
    [No Abstract]   [Full Text] [Related]  

  • 12. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease.
    Renda G; Ricci F; Giugliano RP; De Caterina R
    J Am Coll Cardiol; 2017 Mar; 69(11):1363-1371. PubMed ID: 28302287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to define valvular atrial fibrillation?
    Fauchier L; Philippart R; Clementy N; Bourguignon T; Angoulvant D; Ivanes F; Babuty D; Bernard A
    Arch Cardiovasc Dis; 2015 Oct; 108(10):530-9. PubMed ID: 26184867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of potential roles of combinatorial microRNA regulation in occurrence of valvular heart disease with atrial fibrillation based on computational evidences.
    Wang G; Rao N; Liu D; Jiang H; Liu K; Yang F; Chen Y; Huang K
    PLoS One; 2019; 14(9):e0221900. PubMed ID: 31479479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid gland in chronic obstructive pulmonary disease.
    Miłkowska-Dymanowska J; Białas AJ; Laskowska P; Górski P; Piotrowski WJ
    Adv Respir Med; 2017; 85(1):28-34. PubMed ID: 28198991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study.
    Raparelli V; Pastori D; Pignataro SF; Vestri AR; Pignatelli P; Cangemi R; Proietti M; Davì G; Hiatt WR; Lip GYH; Corazza GR; Perticone F; Violi F; Basili S;
    Intern Emerg Med; 2018 Aug; 13(5):651-660. PubMed ID: 29582316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Atrial fibrillation concomitant with valvular heart disease].
    Ishii Y
    Nihon Rinsho; 2013 Jan; 71(1):136-41. PubMed ID: 23631185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calpain-Calcineurin-Nuclear Factor Signaling and the Development of Atrial Fibrillation in Patients with Valvular Heart Disease and Diabetes.
    Zhao Y; Cui GM; Zhou NN; Li C; Zhang Q; Sun H; Han B; Zou CW; Wang LJ; Li XD; Wang JC
    J Diabetes Res; 2016; 2016():4639654. PubMed ID: 27123462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease.
    Briasoulis A; Inampudi C; Akintoye E; Alvarez P; Panaich S; Vaughan-Sarrazin M
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29622591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma beta-thromboglobulin and platelet factor 4 concentrations in patients with atrial fibrillation.
    Yamauchi K; Furui H; Taniguchi N; Sotobata I
    Jpn Heart J; 1986 Jul; 27(4):481-7. PubMed ID: 2946878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.